La vendita allo scoperto per TransCode Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di TransCode Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

TransCode Therapeutics (NASDAQ:RNAZ) Azioni, Report sulle vendite allo scoperto

TRANSCODE THERAPEUTICS INC

TransCode Therapeutics

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

New,York,Ny - usa-may,5,,2015,Packages,Of,Tyson,Brand,Chicken

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

HSIC

RNAZ

Wall Street guarda ai report trimestrali di importanti aziende come Tyson Foods e Cummins. Scopri i dettagli.

Tyson Foods, Ford e altre 3 azioni da tenere d&#39;occhio in questo lunedì

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

Cryptocurrency markets are trading sideways on Monday morning as markets await <a href="https://www.benzinga.com/news/politics/25/07/46267477/trump-threatens-10-additional-tariff-on-all-brics-aligned-nations-says-tariff-letters-drop-at-noon-monday">tariff-related news</a>. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$108,728.80</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,561.25</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$152.46</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.29</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1712</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001175</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin's large transcation volume and daily active addresses increasing by 3.9% and 6.5%, respectively. </li>
<li>Coinglass data shows 61,019 traders were liquidated in the past 24 hours for $179.64 million.</li>
<li>SoSoValue data shows net inflows of $601.9 million into spot Bitcoin ETFs on July 3, while spot Ethereum ETFs saw net inflows of $148.6 million.</li>
</ul>
Trader Notes: Crypto trader Rekt Capital highlighted that Bitcoin just posted its highest-ever weekly close, breaking through a key resistance level. A successful retest could trigger a breakout toward new all-time highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> Bitcoin has done it Bitcoin has just about Weekly Closed above the final major Weekly resistance (red), registering its highest ever Weekly Close The goal for Bitcoin now is to turn this final resistance into support to springboard price to new All time Highs<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>… <a href="https://t.co/6VY0T7M0kb">https://t.co/6VY0T7M0kb</a> <a href="https://t.co/jjkJneczPz">pic.twitter.com/jjkJneczPz</a>
&mdash; Rekt Capital (@rektcapital) <a href="https://twitter.com/rektcapital/status/1942138317232853465?ref_src=twsrc%5Etfw">July 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite the gains, Glassnode data <a href="https://x.com/glassnode/status/1942135179352408225">shows</a> signs of a summer slowdown, with spot volume at $5.02 billion and futures volume at $31.2 billion, both at their lowest in over a year and continue to decline.
Crypto McKenna <a href="https://x.com/Crypto_McKenna/status/1942151689621946766">turned</a> bullish on Ethereum, noting bearish sentiment as a contrarian signal. He cited mass removals of ".eth" from X usernames and emphasized Ethereum's dominance in stablecoins. He expects the Genius Act to fuel on-chain activity and push ETH well above $3,000.
His conclusion that &#8220;hated assets have hated rallies,&#8221; suggests that negative sentiment could fuel a sharp upside.
CryptosBatman <a href="https://x.com/CryptosBatman/status/1942162173754802311">pointed </a>to strong support and surging demand for tokenized stocks on-chain. Wallets tied to these assets jumped from 4,400 to over 33,000 in 48 hours, suggesting large-scale accumulation and bigger moves ahead.
Dogecoin is forming a double bottom, with Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1942146343490953624">setting</a> an upside target of $0.476.
Meanwhile, XRP is approaching a key selling wall, and trader CW predicts a breakout attempt is imminent.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> will soon attempt to break through the selling wall. <a href="https://t.co/kOpKA5Cilf">pic.twitter.com/kOpKA5Cilf</a>
&mdash; CW (@CW8900) <a href="https://twitter.com/CW8900/status/1942157701565542871?ref_src=twsrc%5Etfw">July 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46260174/this-bitcoin-collector-turned-500-into-over-10-million-by-selling-100-physical-bitcoin">This Bitcoin Collector Turned $500 Into Over $10 Million By Selling 100 &#8216;Physical&#8217; Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Trade Sideways As Trading Volume Decreases

Apogee Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday.
This substantial increase in stock price follows the release of positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody, for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">moderate-to-severe atopic dermatitis</a>.
Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44084945/apogee-therapeutics-investigational-atopic-dermatitis-potential-shows-strong-tolerability-extended-half-life-in-early-trial" rel="noreferrer noopener">Apogee Therapeutics&#8217; Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial</a>
Part A of the trial enrolled 123 adult patients who were randomized 2:1 to APG777 versus placebo and received an induction regimen dosing of 720mg at Weeks 0 and 2, followed by 360mg <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46269848/apogee-therapeutics-announces-positive-16-week-data-from-phase-2-apex-clinical-trial-of-apg777-its" rel="noreferrer noopener">at Weeks 4 and 12</a>.
Patients benefiting from treatment continued maintenance dosing, evaluating 3- or 6-month dosing of APG777.
The primary endpoint of Part A is the mean percentage change in Eczema Area Severity Index (EASI) score from baseline at Week 16.
Secondary endpoints include EASI-75, EASI-90, Validated Investigator Global Assessment (IGA) 0/1, and Itch Numeric Rating Scale (NRS) at Week 16.
On Monday, the company said the trial met its primary endpoint, with APG777 showing significantly greater least squares mean percent change from baseline at Week 16 with an EASI reduction of 71.0% compared to placebo of 33.8% (p &lt; 0.001).
Highest absolute and placebo-adjusted EASI-75 of any biologic, with 66.9% of participants treated with APG777 achieving EASI-75 compared to 24.6% on placebo.
Pre-specified sensitivity analysis showed consistent results in both moderate and severe patients.
Additionally, an exposure-response relationship was observed, with patients in the two highest quartiles of exposures achieving the highest EASI-75 response at Week 16, 83.3% for quartile three and 89.5% for quartile four.
Additional key secondary endpoints were in line with the standard of care, including vIGA 0/1 (Validated Investigator Global Assessment of clear or almost clear skin) of 34.9% compared to 17.3% for placebo, and EASI-90 (Eczema Area Severity Index, 90% improvement) of 33.9% compared to 14.7% for placebo.
Patients in the highest quartile of exposures achieved the highest response, 63.2% vIGA 0/1 and 63.2% EASI-90 at Week 16. Treatment of patients with APG777 led to a rapid onset of itch relief and achieved a statistically significant reduction by Week 1.
50.7% reduction of Itch NRS from baseline compared to 23.2%. APG777 was well tolerated with a safety profile consistent with other agents in the class.
APEX Part B is a placebo-controlled dose optimization with approximately 280 patients randomized 1:1:1:1 to high, medium, or low dose APG777 versus placebo.
Part B continues to enroll participants, with a readout expected in mid-2026. Data readout from the maintenance phase of APEX Part A, testing 3- and 6-month maintenance dosing, is expected in the first half of 2026.
In other news from Apogee Therapeutics, in May, the company revealed interim data from its Phase 1b trial of APG808 for <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45357154/why-is-apogee-therapeutics-stock-trading-higher-on-monday" rel="noreferrer noopener">mild-to-moderate asthma</a>.
The study showed that a multiple-dose regimen of APG808 was well tolerated in asthmatic patients through 12 weeks of available follow-up. The most common treatment-emergent adverse events observed were headache, injection site erythema, and upper respiratory tract infections.
Price Action: APGE stock is trading higher by 28.9% to $61.20 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/07/46270121/capgemini-doubles-down-on-agentic-ai-with-3-3-billion-wns-acquisition" target="_blank" rel="noreferrer noopener">Capgemini Doubles Down On Agentic AI With $3.3 Billion WNS Acquisition</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

APGE

Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial

Australian miner South32 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOUHY#NYSE">SOUHY</a>) has agreed to sell its Cerro Matoso <a target="_blank" href="https://www.benzinga.com/topic/nickel" rel="noreferrer noopener">ferronickel mine</a> in northern Colombia to an industrial conglomerate, CoreX Holding, in a deal valued at up to $100 million.
The <a target="_blank" href="https://www.south32.net/news-media/latest-news/agreement-to-sell-cerro-matoso" rel="noreferrer noopener">agreement</a> includes a nominal upfront payment, with additional payments tied to future nickel prices and production performance, as well as up to $20 million in permitting milestone bonuses over the next five years.
Cerro Matoso, located in Córdoba, Colombia, is one of the leading global open-pit ferronickel operations but has struggled amid the weakening market. South32 reported a 6% drop in nickel output in the nine months ending March 2025 due to lower planned grades. The firm will also record a $130 million impairment loss, which will be excluded from the company's underlying earnings.
"The deal supports our strategy to streamline the portfolio and focus on higher-margin commodities essential for the green transition, such as copper and zinc," South32 <a target="_blank" href="https://www.south32.net/news-media/latest-news/agreement-to-sell-cerro-matoso" rel="noreferrer noopener">said</a> in a statement. The Perth-based miner continues to operate major assets across Australia, South Africa, and South America, focusing on copper and zinc.
The asset sale is unsurprising, given the recent <a target="_blank" href="https://www.benzinga.com/news/24/01/36737765/nickels-nosedive-40-yearly-drop-puts-miners-in-a-tight-spot" rel="noreferrer noopener">nickel market dynamics</a>. Prices have plummeted due to massive output from Indonesia, the world's top producer. Following the highs of $48,000 per ton reached in early 2022, prices dropped as low as $13,865 per ton in April.
Even China's Tsingshan Holding Group suspended multiple smelting lines at its Morowali facility in Central Sulawesi in May 2025, placing them under open-ended maintenance.
Macquire analyst Jim Lennon expects the surplus to continue until 2027-2028. "The market is in oversupply, and in Indonesia, several projects in the pipeline will be completed soon, increasing production capacity," he said at the May Shanghai Metals Market conference in Jakarta, according <a target="_blank" href="https://www.reuters.com/markets/commodities/nickel-oversupply-persist-expansion-slower-demand-growth-industry-experts-say-2025-06-05/" rel="noreferrer noopener">to</a> Reuters.
However, some leading industry names oppose this stance. Veteran resource investor Rick Rule sees a turning point for Indonesia. "The environmental degradation in Sulawesi won't be tolerated much longer," he <a target="_blank" href="https://www.youtube.com/watch?v=a8PHsOmA9rA" rel="noreferrer noopener">noted</a> in a recent interview.
Rule has long favored high-grade sulfide nickel over Indonesia's laterite deposits, citing their lower energy intensity. "As oil prices rise over the next two to three years, the cost of laterite nickel will soar," he warned.
Some backlash is already materializing. AP News <a target="_blank" href="https://apnews.com/article/indonesia-raja-ampat-nickel-mining-suspend-a73cccb78485f7c8e3e785193d0bbede" rel="noreferrer noopener">reported</a> that last month, the Indonesian government suspended nickel mining in Raja Ampat—an ecologically fragile archipelago often referred to as the "Amazon of the seas." Violations included illegal mining on protected islands, pollution, and unpermitted land use.
Rule remains bullish, taking a contrarian stance but preferring quality over scale. "Sulfide nickel has made me a lot of money. In natural resource investing, you're either a contrarian or you're going to be a victim," he concluded.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/07/46266270/aluminerie-alouette-to-invest-1-1-billion-in-major-canadian-aluminum-revamp" target="_blank" rel="noreferrer noopener">Aluminerie Alouette to Invest $1.1 Billion in Major Canadian Aluminum Revamp</a></li>
</ul>
Photo via Shutterstock

Equities

Financing

Commodities

Asset Sales

Global

SOUHY

Nickel Downturn Prompts South32 Divestment, Veteran Investor Eyes Contrarian Opportunity

Jefferies analyst Kaumil Gajrawala upgrades Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Hold to Buy and raises the price target from $194 to $205.

Upgrades

Price Target

Analyst Ratings

Jefferies Upgrades Constellation Brands to Buy, Raises Price Target to $205

TSLA: -6% &#x7C; <a href="https://www.benzinga.com/node/46270992">Tesla shares are trading lower after CEO Elon Musk said he would launch a political party.</a>
&nbsp;
COGT: 25% &#x7C; <a href="https://www.benzinga.com/node/46271019">Cogent Biosciences shares are trading higher after the company announced topline results from Part 2 of the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, showing clinically meaningful and statistically significant improvements across the primary and all key secondary endpoints.</a>
&nbsp;
BULL: -6% &#x7C; <a href="https://www.benzinga.com/node/46271008">Webull shares are trading lower after the company announced a $1 billion standby equity agreement Thursday after the market closed.</a>

BULL

COGT

TSLA

Market-Moving News for July 7th

OR Royalties Inc. ("OR Royalties" or the "Company") (OR: TSX &amp; NYSE) is pleased to provide an update on its second quarter 2025 preliminary deliveries, revenues and cash margin, as well as on its cash and debt positions as at June 30th, 2025. All monetary amounts included in this report are expressed in United States dollars, unless otherwise noted.
PRELIMINARY Q2 2025 RESULTS
OR Royalties earned 19,700 attributable gold equivalent ounces1 ("GEOs") in the second quarter of 2025.
OR Royalties recorded preliminary revenues from royalties and streams of $60.4 million during the second quarter, a quarterly record, and preliminary cost of sales (excluding depletion) of $2.6 million, resulting in a record quarterly cash margin2 of approximately $57.8 million (95.8%).
As at June 30th, 2025, OR Royalties' cash position was approximately $49.6 million, following repayments of $40.0 million on the Company's revolving credit facility during the second quarter. OR Royalties' revolving credit facility was drawn by $35.7 million at the end of June 2025, with an additional amount of $614.3&nbsp;million available to be drawn plus the uncommitted accordion of $200.0 million.

OR Royalties Reports Q2 Preliminary Revenues From Royalties And Streams Of $60.4M; Earns 19,700 Attributable GEOs In Q2

IREN Limited (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data=r2RGPOHNIUr0R4k8-W7YQ4vqPTzmujE8M-MBI7EeK5pFK0Czvn3PnkVqz-HXH4HF">IREN</a>) (together with its subsidiaries, "IREN" or "the Company"), today published its monthly update for June 2025.
June Highlights
<ul>
<li>Record monthly revenue and hardware profit3</li>
<li>50 EH/s mid-year target achieved</li>
<li>AI Cloud expanded with ~2.4k Blackwell GPUs</li>
<li>$550m convertible notes offering oversubscribed</li>
<li>US domestic issuer status transition complete</li>
<li>Customer and financing workstreams progressing across AI verticals</li>
</ul>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Key Metrics</td>
<td colspan="2">Jun 25</td>
<td>May 25</td>
</tr>
<tr>
<td>Bitcoin Mining</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Average operating hashrate</td>
<td colspan="2">41.1 EH/s</td>
<td>38.4 EH/s</td>
</tr>
<tr>
<td>Bitcoin mined4</td>
<td colspan="2">620 BTC</td>
<td>627 BTC</td>
</tr>
<tr>
<td>Revenue per Bitcoin mined</td>
<td colspan="2">$105,730</td>
<td>$103,345</td>
</tr>
<tr>
<td>Net electricity cost per Bitcoin mined2</td>
<td colspan="2">($26,259)</td>
<td>($27,033)</td>
</tr>
<tr>
<td>Revenue</td>
<td colspan="2">$65.5m</td>
<td>$64.7m</td>
</tr>
<tr>
<td>Net electricity costs1</td>
<td colspan="2">($16.3m)</td>
<td>($16.9m)</td>
</tr>
<tr>
<td>Hardware profit3</td>
<td colspan="2">$49.2m</td>
<td>$47.8m</td>
</tr>
<tr>
<td>Hardware profit margin5</td>
<td colspan="2">75%</td>
<td>74%</td>
</tr>
<tr>
<td>AI Cloud Services</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td colspan="2">$2.2m</td>
<td>$2.2m</td>
</tr>
<tr>
<td>Net electricity costs1</td>
<td colspan="2">($0.03m)</td>
<td>($0.03m)</td>
</tr>
<tr>
<td>Hardware profit3</td>
<td colspan="2">$2.1m</td>
<td>$2.1m</td>
</tr>
<tr>
<td>Hardware profit margin5</td>
<td colspan="2">98%</td>
<td>98%</td>
</tr>
</tbody>
</table>
</figure>

IREN

IREN Hits Record Revenue in June, Mining 620 Bitcoin and Expands AI Cloud With 2,400 GPUs










Ask ChatGPT

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and maintains $24 price target.

Telsey Advisory Group Maintains Outperform on Albertsons Companies, Maintains $24 Price Target

WIIM

Molina shares are trading lower after the company guided Q2 EPS to $5.50 vs the $6.21 estimate and cut its full-year EPS outlook amid rising medical costs.

Cogent Biosciences shares are trading higher after the company announced topline results from Part 2 of the SUMMIT trial of bezuclastinib for non-advanced systemic mastocytosis, showing clinically meaningful and statistically significant improvements across the primary and all key secondary endpoints.

Webull shares are trading lower after the company announced a $1 billion standby equity agreement Thursday after the market closed.

Tesla shares are trading lower after CEO Elon Musk said he would launch a political party.

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) will release earnings results for the second quarter, before the opening <a href="https://www.benzinga.com/quote/JPM/earnings">bell on Tuesday, July 15.</a>
Analysts expect the New York-based company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 1, JPMorgan announced a dividend increase and authorized a new buyback. The company's board announced that it intends to increase the quarterly stock dividend from $1.40 per share to $1.50 per share for the third quarter.
JPMorgan shares gained 1.9% to close at $296.00 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/jpm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating and raised the price target from $280 to $298 on July 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Keith Horowitz maintained a Neutral rating and boosted the price target from $250 to $275 on June 26, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Morgan Stanley analyst Betsy Graseck maintained an Equal-Weight rating and boosted the price target from $236 to $240 on June 23, 2025. This analyst has an accuracy rate of 61%.</li>
<li>B of A Securities analyst Ebrahim Poonawala maintained a Buy rating and raised the price target from $300 to $325 on June 18, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst Mike Mayo maintained an Overweight rating and boosted the price target from $300 to $320 on June 10, 2025. This analyst has an accuracy rate of 70%</li>
</ul>
Considering buying JPM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/JPM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-1024x586.png" alt="" class="wp-image-974060" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07015445/image-52.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

JPMorgan Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">EPWK Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>)</h3>
<ul class="wp-block-list">
<li>On May 27, EPWK Holdings posted a H2 loss of 3 cents per share. The company's stock fell around 15% over the past month and has a 52-week low of $0.41.</li>
<li>RSI Value: 24.5</li>
<li>MKZR Price Action: Shares of EPWK Holdings fell 3.3% to close at $0.50 on Thursday.</li>
<li>Edge Stock Ratings: Value at 35.23. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/EPWK"><img loading="lazy" decoding="async" width="408" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56.png" alt="" class="wp-image-974564" style="width:291px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56.png 408w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070633/image-56-300x134.png 300w" sizes="(max-width: 408px) 100vw, 408px" /></a></figure>
<h3 class="wp-block-heading">HUYA Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>)</h3>
<ul class="wp-block-list">
<li>On May 13, HUYA posted first-quarter adjusted earnings of 1 cent per share. Mr. Junhong Huang, Acting Co-Chief Executive Officer and Senior Vice President of Huya, commented, &#8220;During the first quarter of 2025, we continued to strengthen our live streaming content ecosystem, deepen collaborations with game companies and content platforms, and effectively implement our strategic business transformation.&#8221; The company's stock fell around 40% over the past month and<a href="https://www.benzinga.com/quote/HUYA"> has a 52-week low</a> of $0.080.</li>
<li>RSI Value: 26.1</li>
<li>HUYA Price Action: Shares of HUYA closed at $2.47 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">HUYA stock</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="920" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57.png" alt="" class="wp-image-974568" style="width:710px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070744/image-57-768x694.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Gibo Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>)</h3>
<ul class="wp-block-list">
<li>On June 30, GIBO Holdings announced the successful testing of its AI-driven engine, GIBO Click, on uDrama, a rising star in the global short drama landscape.. The company's stock fell around 96% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/GIBO">low of $0.082</a>.</li>
<li>RSI Value: 10.1</li>
<li>GIBO Ltd Price Action: Shares of Gibo Holdings dipped 29.6% to close at $0.084 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">RETO shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="882" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58.png" alt="" class="wp-image-974576" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07070908/image-58-768x702.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

EPWK

GIBO

HUYA

Top 3 Tech And Telecom Stocks That Are Set To Fly In Q3

<ul>
<li>Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population.</li>
<li>Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo.</li>
<li>Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population.</li>
<li>Bezuclastinib NDA submission to FDA expected by end of 2025; strong financial position with $237 million current cash balance and access up to an additional $350 million via recently announced debt facility with SLR Capital Partners.</li>
<li>On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025</li>
</ul>

Cogent Biosciences Announces Topline Results From Part 2 Of The SUMMIT Trial Of Bezuclastinib For Non-advanced Systemic Mastocytosis, Demonstrating Clinically Meaningful And Highly Statistically Significant Improvements Across The Primary And All Key Secondary Endpoints

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox
TNX-801 confers durable protection after a single dose
TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses
CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) ("Tonix" or the "Company"), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Sina Bavari, PhD, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present new data on TNX-801 (recombinant horsepox virus, live vaccine) at the upcoming Vaccine Congress 2025.
TNX-801 is a minimally replicative, attenuated live virus vaccine candidate designed to generate durable humoral and cellular immunity after a single dose. Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens.
Dr. Bavari will present the safety, immunogenicity, and efficacy findings to date and describe Tonix's plans to advance the TNX-801 platform into clinical trials to protect against mpox and other viral diseases.

TNXP

Tonix Pharma To Present New Data On TNX-801, Recombinant Horsepox Virus, Live Vaccine, At Upcoming Vaccine Congress 2025

The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>), the nation's largest franchisor of chiropractic care through The Joint Chiropractic&#xAE; network, closed the sale of 31 corporate owned and managed clinics and associated franchise licenses in Arizona and New Mexico to Joint Ventures, LLC in exchange for $8.3 million in cash and the regional developer (RD) territory rights of the Northwest region that generated $855,000 in royalties and franchise fees over the 12 months ended March 31, 2025. "Our goal for the refranchising initiative is to strengthen and simplify our business, while ensuring our clinics go to proven franchise operators that can improve performance and grow within their regions," said The Joint Corp.'s President, Chief Executive Officer and Director Sanjiv Razdan. "We are very happy that Joint Ventures, one of our strongest franchisees, is purchasing 31 clinics in Arizona and New Mexico. As part of the consideration for the clinics, we are acquiring Joint Ventures' regional developer rights for the Northwest region, covering 46 existing franchised clinics and 30 sites for future clinic development. By acquiring RD rights, we will reduce commission obligations and increase operating margin, as these clinics incurred $855,000 in royalties and commissions under these RD rights in the trailing twelve months ended March 31, 2025. By increasing their stake in The Joint, existing franchisees are validating our initiatives to strengthen the patient experience, drive revenue and reduce operational costs. We expect to deploy our expanding working capital to generate value for stockholders."

JYNT

The Joint Sells 31 Clinics for $8.3M, Gains Control of Profitable Northwest Franchise Region

Heidmar Maritime Holdings Corp. (the "Company" or "Heidmar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>) today announces its first vessel acquisition, making it a strategic milestone in the Company's project development and growth strategy.
Heidmar has entered into an agreement to acquire C/V A. Obelix, a 1,702 TEU cellular/gearless feeder container vessel, built in 2008 at Wadan/Aker Yards, Wismar Germany. C/V A. Obelix is classed by Lloyd's Register and has been strengthened for Ice Class II operations. The vessel is powered by a two-stroke main engine and is equipped with a bow thruster, allowing for a high degree of maneuverability and independence in port operations, and a high-capacity 330-plug reefer system. The vessel's next drydock is scheduled for 2028 allowing for three clear years of operations with no projected upfront maintenance expense.
Heidmar is acquiring its interest in the vessel from a related party at an aggregate purchase price of $25.25 million. The security of the charter revenue and the end-of-life recycling price are expected to effectively cover the cost of the acquisition in case of the high EBITDA scenario.

Heidmar Maritime Agrees To Acquire Cellular/Gearless Feeder Container Vessel, C/V A. Obelix, For $25.25M

Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sand#NYSE">SAND</a>) (TSX:SSL) is pleased to announce that the Company has entered into a definitive arrangement agreement with Royal Gold Inc.
Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SSL#TSX">SSL</a>) is pleased to announce that the Company has entered into a definitive arrangement agreement with Royal Gold Inc. ("Royal Gold"), pursuant to which Royal Gold will acquire all of the issued and outstanding common shares of Sandstorm (the "Sandstorm Shares") in an all-share transaction with an implied value of approximately $3.5&nbsp;billion (the "Sandstorm Transaction"). Sandstorm shareholders will receive 0.0625 of a share of common stock of Royal Gold (each whole share, a "Royal Gold Share") for each Sandstorm Share held, implying a 21% premium to the 20-day volume-weighted average price ("VWAP") of the Sandstorm Shares for the period ended July 3, 2025, and a 17% premium to the closing price of the Sandstorm Shares on the New York Stock Exchange (the "NYSE") on July 3, 2025. Upon closing, existing Royal Gold and Sandstorm shareholders will own approximately 77% and 23%, of the issued and outstanding Royal Gold Shares on a fully diluted basis.

RGLD

SAND

Sandstorm Gold Enters Agreement With Royal Gold, Under Which Royal Gold Will Acquire All Issued And Outstanding Shares Of Sandstorm In All-Share Deal With Implied Value Of $3.5B

NTRA

Natera Highlights Clinical Results From CIRCULATE-Japan Study, Demonstrating Latitude MRD Assay's Prognostic And Predictive Value

Offerings

Press Releases

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

Comments

TransCode Therapeutics

Vendite allo scoperto

TransCode Therapeutics (NASDAQ:RNAZ) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO